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Expanded Abstract 
Citation 
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multiple-organ dysfunction syndrome: a multicentre 
randomised trial.  Lancet  2006;368(9533):379-85 [1]. 
Background 
Whether continuous renal replacement therapy is better 
than intermittent haemodialysis for the treatment of acute 
renal failure in critically ill patients is controversial.  
Methods 
Objective: To compare the effect of intermittent 
haemodialysis and continuous venovenous 
haemodiafiltration on survival rates in critically ill patients 
with acute renal failure as part of multiple-organ dysfunction 
syndrome. 
Design: Prospective, randomized, controlled trial 
Setting: 21 medical or multidisciplinary intensive-care units 
from university or community hospitals in France between 
Oct 1, 1999 and March 3, 2003. 
Subjects: 360 critically ill patients with acute renal failure as 
part of multiple-organ dysfunction syndrome. 
Intervention: Patients were randomized to intermittent 
haemodialysis (n=184) or continuous venovenous 
haemodiafiltration (n=175). Guidelines were provided to 
achieve optimum haemodynamic tolerance and 
effectiveness of solute removal in both groups. The two 
groups were treated with the same polymer membrane and 
bicarbonate-based buffer.  
Measurements and main results: The primary endpoint 
was 60-day survival based on an intention-to-treat analysis. 
Rate of survival at 60-days did not differ between the groups 
(32% in the intermittent haemodialysis group versus 33% in 
the continuous renal replacement therapy group [95 % CI -
8.8 to 11.1,]), or at any other time. 
Conclusion 
These data suggest that, provided strict guidelines to 
improve tolerance and metabolic control are used, almost all 
patients with acute renal failure as part of multiple-organ 
dysfunction syndrome can be treated with intermittent 
haemodialysis. 
Commentary 
Acute renal failure occurs frequently in critically ill patients 
and is associated with mortality as high as 60% [2]. The 
goal of renal replacement therapy is to achieve adequate 
correction of uremia, electrolyte abnormalities, and volume 
overload while ensuring good hemodynamic tolerance. 
Since it was first described in 1977, continuous renal 
replacement therapy (CRRT) has become an increasingly 
popular alternative to intermittent hemodialysis (IHD) in 
critically ill patients. The theoretical advantages of CRRT 
are increased time-averaged dialysis dose, less 
hemodynamic instability, and, possibly, removal of high 
molecular weight solutes, such as inflammatory cytokines 
[3].  
Despite its potential clinical advantages, CRRT has not 
been shown to be superior to IHD. Several studies 
compared CRRT to IHD using retrospective observational 
designs, with inherent differences between treatment 
groups, such as type of dialysis membrane used and 
baseline illness severity, limiting the usefulness of their 
findings. Three prospective randomized trials have 
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compared CRRT to IHD. One study suggested that CRRT 
increased mortality [4], though imbalanced randomization 
biased the study against CRRT. After adjusting for 
disproportionally distributed covariates, mortality did not 
differ between groups. The other two randomized studies 
failed to show a difference for mortality or other endpoints, 
but were small and underpowered [5,6]. 
The current study by Vinsonneau and colleagues is the 
latest attempt at determining which modality is superior.  A 
heterogeneous group of 360 medical and surgical ICU 
patients with acute renal failure as part of the multiple organ 
dysfunction syndrome (MODS) were randomized to CRRT 
(specifically, continuous venovenous hemodiafiltration) 
versus IHD in 21 ICUs throughout France. At study entry, 
nearly all subjects were mechanically ventilated, almost 
90% were on vasopressors, and more than half had sepsis. 
Guidelines were provided to achieve optimum metabolic 
control and hemodynamic stability. For CRRT, this included 
a blood flow of 120 mL/min or more with the objective to 
maintain urea concentration at less than 30 mmol/L. For 
IHD, the recommendation was to keep a blood flow of 250 
mL/min or more with the objective of a urea reduction ratio 
greater than 65% for each session. The study used the 
same membranes in each group and there was no 
measurement of the delivered dialysis dose once treatment 
was initiated. The authors found that there was no 
difference in mortality, ICU or hospital length of stay, or rate 
and time to renal recovery. There were no differences in 
adverse event rates, such as hypotension or 
thrombocytopenia, though the CRRT group did develop 
hypothermia more frequently (17% vs. 5%, p=0.0005). The 
authors concluded that, provided strict guidelines to improve 
tolerance and metabolic control, almost all patients with 
acute renal failure as part of MODS can be treated with IHD. 
This was a well-conducted study with successful 
randomization ensuring balance in clinically important 
patient characteristics at baseline. A few limitations, 
however, deserve consideration. The study was relatively 
small and only powered to detect a 15% absolute difference 
in 60-day mortality. With a 1.1% absolute difference in 
mortality rates, it is difficult to imagine there is a clinically 
meaningful difference in outcome between groups. Proving 
statistical significance would have required a study two 
orders of magnitude larger in size. The “dose” of therapy 
was not specified in either group. The average delivered 
dose in the CRRT group (29 mL/kg/hr) was below the dose 
shown to improve survival (35mL/kg/hr) in the one recent 
study [7]. There was no assessment of the delivered dose in 
the IHD group once treatment was started. Thus, the 
delivered dose in both arms might have been suboptimal. 
Additionally, there is a lack of information about subsequent 
co-interventions, such as vasopressor and fluid therapy, 
which could have been used differentially between groups 
in this non-blinded study and, therefore, influenced 
mortality. Finally, there is a curious finding that the mortality 
rate in the IHD group decreased significantly overtime, 
whereas mortality in the CRRT group remained stable. 
Though changes in the dialysis membrane were made by 
the manufacturer mid-study [8], these did not appear to 
have any effect on mortality. Nor could the change in 
survival be explained by changes in case-mix or a center-
specific effect. The authors raise the possibility that 
standard of care improvements during the study could have 
favored IHD, but found no evidence of such an effect in an 
analysis of a similar patient population treated with IHD in 
France during the same period [9]. 
Recommendation 
Based on the results of this study, is appears that virtually 
all critically ill patients with acute renal failure and MODS 
can be treated with intermittent hemodialysis if appropriate 
attention is paid to hemodynamic and metabolic control. 
Questions such as whether a specific patient will do better 
with a particular modality or the optimal time to switch from 
one method to the other are unanswered by this study and 
may depend, at least in part, upon the level of expertise of a 
particular center with each modality. 
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